Iconic Labs plcLSE: ICON

Iconic Labs: Conversion of Notes and Allotment of Shares

· Issued by Iconic Labs PLC via RNS

Summary by 6ix AI

Iconic Labs PLC received a valid conversion notice dated October 23, 2026 to convert 1 convertible note with a principal amount of £5,000 into 416,667 new ordinary shares at a conversion price of GBP 0.0120 per share.

Key details

  • The company is applying for the 416,667 new ordinary shares, with a nominal value of £0.0001 each, to be admitted to trading on the Main Market of the London Stock Exchange.
  • The new shares rank equally (pari passu) with the existing ordinary shares.
  • Following the issue, the company's issued ordinary share capital will consist of 18,415,202 ordinary shares, which is also the total number of voting rights in the company.

What’s still pending

  • Admission of the new shares to trading is expected on or around October 30, 2026.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/conversion-of-notes-and-allotment-of-shares-2

Iconic Labs PLC
26 October 2026

Iconic Labs PLC

("Iconic" or the "Company")

Conversion of Notes and Allotment of Shares

Iconic Labs PLC (LSE:ICON), announces that it has received a valid Conversion Notice.

The Conversion Notice was dated 23 October 2026 and provides for 1 Convertible Note to be converted into 416,667 ordinary shares of £0.0001 in the Company ("Ordinary Shares") at a conversion price of GBP 0.0120 at the aggregate principal amount of £5,000.

Application is therefore being made for an aggregate of 416,667 new Ordinary Shares to be admitted to trading on the Main Market of the London Stock Exchange which is expected to be on or around 30 October 2026. These shares rank pari passu with the existing Ordinary Shares of the Company.

Following the issue of these shares, the Company's issued ordinary share capital shall consist of 18,415,202 Ordinary Shares. The figure of 18,415,202 represents the total voting rights in the Company and should be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance & Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

For any further information or enquiries please contact:

Iconic Labs

John Farquharson, Chief Executive Officer

via Yellow Jersey PR

AlbR Capital Limited

David Coffman / Daniel Harris

Tel: +44 (0) 20 7469 0930

Yellow Jersey PR

Charles Goodwin

Tel: +44 (0) 20 3004 9512

[email protected]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

Iconic Labs plc on 6ix

Story so far

Earlier from Iconic Labs

All Iconic Labs news releases